Early Parkinson Disease
Key Points
Key Points
- The treatment options for the alleviation of motor symptoms in the early stages of Parkinson disease (PD) are based on the enhancement of dopaminergic tone with levodopa, monoamine oxidase inhibitors, dopamine agonists (DAs), or a combination thereof.
- The choice of initial treatment is influenced by the potential for neuropsychiatric adverse effects associated with DAs and dyskinesia and motor fluctuations associated with levodopa.
Treatment
...eatment...
...vs. DAs vs. MAO-B inhibitors
...nicians should counsel patients with early PD on...
...h early PD who seek treatment for motor symp...
...may prescribe DAs as the initial dopaminergic th...
...uld not prescribe DAs to patients with early...
...rescribing levod...
...should initially prescribe immediat...
...tients with early PD, clinicians should prescri...
...should routinely monitor patients tak...
...inicians should counsel patients taking l...
...inicians should counsel patients that i...
...ribing DAs
Clinicians should inform the patient...
...inicians should screen patients for...
Clinicians should screen patients for the presence...
...icians should involve caregivers in assessme...
...screen patients for the presence of adverse...
...uld integrate patient preferences c...
...ians should prescribe the lowest d...
...apering and Discontinuing DAs...
...inicians should recommend tapering or discontin...
...discontinued due to adverse effects, clinic...
...scribing MAO-B inhibito...
...ns should counsel patients with early P...
...may prescribe MAO-B inhibitors as the initial do...
...or Parkinson DiseaseHaving trouble viewing ta...